GlassScriptPhysician profile
Garrett Diltz
NPI 1578120176
$3,878.29
in general payments reported to CMS, 2019-2025
46 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $920 · 2023: $491 · 2024: $193 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,761 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,760.70 |
| Education | $197.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $367.30 | 2025 | Tecvayli, Erleada, Darzalex |
| Amgen INC. | $309.14 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $234.37 | 2023-2025 | Iclusig, Fruzaqla |
| Incyte Corporation | $231.04 | 2022-2025 | Jakafi, Niktimvo |
| Novartis Pharmaceuticals Corporation | $186.59 | 2025 | |
| Foundation Medicine, INC. | $168.96 | 2022 | |
| Merck Sharp & Dohme LLC | $160.61 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $147.84 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $132.74 | 2023-2025 | Orgovyx |
| Seagen INC. | $123.91 | 2022 | |
| Genzyme Corporation | $118.79 | 2022 | |
| Lilly USA, LLC | $114.72 | 2022-2025 | Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $110.53 | 2022 | |
| Daiichi Sankyo INC. | $105.43 | 2025 | Enhertu |
| Progenics Pharmaceuticals, INC. | $97.54 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Diltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.